Overcoming antiangiogenic resistance

Clinical Cancer Research

Volumn 17, Issue 16, 2011, Pages 5217-5219

  Yao, James C ^a   Phan, Alexandria ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; MONOCLONAL ANTIBODY DC101; PAZOPANIB; PEGINTERFERON ALPHA2A; PLACEBO; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR SP1; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BREAST CARCINOMA; CANCER SURVIVAL; CARCINOID; COLON CANCER; COLON CARCINOMA; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TUMOR BLOOD FLOW; UPREGULATION;

ALANINE; ANIMALS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; TRIAZINES;

EID: 80051697787     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1219     Document Type: Short Survey

References (12)

1. Allen E, Walters IB, Hanahan D. Brivanib, a Dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011;17:5299-5310
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
3. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
4. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009;8:1867-1877
5. Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, et al. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res 2007;67:4878-4885 (Pubitemid 46910196)
6. Matrana MR, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Metastatic renal cell carcinoma treated with pazopanib after progression on other targeted agents: a single-institution experience. J Clin Oncol 2011;29(suppl 7):abstr 351.
7. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513
8. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 2007;25(18S):abstr 4504.
9. Phan AT, Yao JC, Fogelman DR, Hess KR, Ng CS, Bullock SA, et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010;28(7s):abstr 4001.
10. von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. [comment]J Natl Cancer Inst 2003;95:437-448 (Pubitemid 36432418)
11. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-1323
12. Ng CS, Charnsangavej C, Wei W, Yao JC. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol 2011;196:569-576